NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 181 filers reported holding NOVOCURE LTD in Q3 2018. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $589,000 | -83.1% | 8,747 | -78.8% | 0.06% | -70.5% |
| Q4 2019 | $3,481,000 | -36.5% | 41,302 | -43.6% | 0.20% | -23.4% |
| Q3 2019 | $5,478,000 | +70.1% | 73,255 | +43.8% | 0.26% | +82.5% |
| Q2 2019 | $3,220,000 | +50.3% | 50,925 | +14.5% | 0.14% | +72.3% |
| Q1 2019 | $2,143,000 | -74.9% | 44,490 | -72.6% | 0.08% | -66.8% |
| Q3 2018 | $8,521,000 | +27.9% | 162,620 | -23.6% | 0.25% | +22.5% |
| Q2 2018 | $6,663,000 | +109.0% | 212,875 | +45.6% | 0.20% | +100.0% |
| Q1 2018 | $3,188,000 | +1.3% | 146,225 | -6.1% | 0.10% | +6.2% |
| Q4 2017 | $3,146,000 | +55.7% | 155,725 | +53.0% | 0.10% | +50.0% |
| Q3 2017 | $2,021,000 | +80.6% | 101,795 | +57.4% | 0.06% | +113.3% |
| Q2 2017 | $1,119,000 | – | 64,685 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |